LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
$1,142.85
-0.61% today · -3.43% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- LLY −0.61% on the last session vs SPY +0.74%: −1.3 pts of stock-specific move.
- 1 analyst action in the past 10 days (1 positive, 0 negative); latest: JP Morgan maintained Overweight, raised target $1,400 → $1,500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Key facts
- Market cap
- $1.02T
- Held by institutions
- 85.3%
- Short interest
- 0.8%
- 52-week range
- 783.85–1,292.65
- Analyst mean target
- $1,328.83
- Next earnings
- Oct 29 BMO
- Forward P/E
- 24.1
Recent events
Analyst ▲
JP Morgan maintained Overweight, raised target $1,400 → $1,500Analyst
TD Cowen reiterated Buy, target $1,250Analyst ▲
Guggenheim maintained Buy, raised target $1,273 → $1,284Analyst ▲
HSBC maintained Reduce, raised target $850 → $940Insider ▼
Patrik Jonsson (EVP & President, LLY Int'l) sold 6,500 shares ($7.6M) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Donald A Zakrowski (SVP, Finance, & CAO) sold 2,000 shares ($2.4M) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Anat Hakim (EVP, GC & Secretary) sold 5,000 shares ($6.0M) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingAnalyst ▲
Truist Securities maintained Buy, raised target $1,370 → $1,376Analyst ▲
Cantor Fitzgerald maintained Overweight, raised target $1,350 → $1,410Analyst ▲
Wells Fargo maintained Overweight, raised target $1,280 → $1,330